Pembrolizumab is currently approved by the FDA in combination with chemotherapy for the treatment of patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 (CPS >10) as determined by an FDA-approved test. ![]() “CPS >10 is a reasonable cut-off to define the population of women with metastatic TNBC expected to derive treatment benefit from pembrolizumab plus chemotherapy.” No new safety concerns emerged during the trial,” Dr Cortés stated. “The study met its dual primary end point, showing a statistically significant and clinically meaningful improvement in progression-free survival and OS for pembrolizumab plus chemotherapy versus chemotherapy alone for the first-line treatment of PD-L1 CPS >10 metastatic TNBC. These findings were presented at the 2021 San Antonio Breast Cancer Symposium by Javier Cortés, MD, PhD, Head, Breast Cancer Unit, IOB Institute of Oncology, Quiron Group, Madrid and Barcelona, Spain, and Clinical Investigator, Breast Cancer Research Program, Vall d’Hebron Institute of Oncology, Barcelona. ![]() Final results from the pivotal phase 3 KEYNOTE-355 trial showed that the addition of pembrolizumab (Keytruda) to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) compared with chemotherapy alone in patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 with a combined positive score (CPS) ≥10.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |